• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Microlut
    / Bayer

    Active Ingredient
    Levonorgestrel 0.03 mg

    Status in Israel

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Film Coated Tablets

    35 x 0.3 mg

    not in the basket chart 86219 13606

    Related information


    First treatment cycle: One tablet daily, starting on the first day of the menstrual cycle, at a time of day chosen by the patient. All subsequent tablets must then be taken at this time. The contraceptive effect is likely to be reduced if a tablet is delayed by more than three hours. Additional contraceptive precautions are not necessary when initiating treatment.
    Subsequent cycles: The tablets are taken daily and pack follows pack without interruption, and without regard to bleeding. Changing from a combined oral contraceptive (COC): The first tablet should be taken on the first day after the last active tablet of the COC pack (In the case of every day (ED) tablet use, the inactive ones should be omitted). Additional contraceptive precautions are not required.
    Changing from another POP: The switch can be made at any time without
    interruption of contraceptive protection. Changing from a progestogen-only parenteral method (implant, injection): The switch should be made before or when the next injection or implant is due.
    Post-partum use: Can be initiated up to 21 days post-partum (no additional contraceptive is required). If started after 21 days additional barrier contraceptive methods should be used for 7 days. However, if intercourse has already occurred, pregnancy should be excluded before the actual start of Microlut use or the woman has to wait for her first menstrual period.
    For full details see prescribing information




    Known or suspected pregnancy. Active venous thromboembolic disorder. Arterial and cardiovascular disease present or in history (e.g. myocardial infarction, cerebrovascular accident, ischemic heart disease). Diabetes mellitus with vascular involvement. Presence or history of severe hepatic disease as long as liver function values have not returned to normal. Presence or history of liver tumors (benign or malignant). Known or suspected sex hormone-dependent malignancies. Undiagnosed vaginal bleeding. Known hypersensitivity to any of the components. Sickle cell anemia. Jaundice or persistent itching during a previous pregnancy.
    See prescribing information for full details.

    Special Precautions

    Circulatory disorders, tumors, hypertension, diabetes, history of extrauterine pregnancy or an impairment of tube function. Administration should be stopped immediately for the following reasons: Occurrence for the first time, or exacerbation of migrainous headaches or unusually frequent or unusually severe headaches. Sudden disturbances of vision or hearing or other perceptual disorders. First signs of thrombophlebitis or thromboembolic symptoms, feeling of pain and tightness in the chest. Six weeks before an elective major operation, any surgery to the legs, medicdbal treatment for varicose veins or prolonged immobilization. Do not restart until 2 weeks after full ambulation. Onset of jaundice, hepatitis, itching of the whole body. Significant rise in blood pressure. Clear exacerbation of conditions known to be capable of deteriorating during oral contraception or pregnancy.
    See prescribing information for full details.

    Side Effects

    Menstrual disturbances (e.g. frequent and/or irregular bleeding, amenorrhea), breast tenderness; headache; nausea; vomiting; dizziness; various skin disorders (including acne and hirsutism); depressive moods, change in body weight; changes in libido, changes in vaginal secretion, contact lens intolerance, hypersensitivity reaction.
    See prescribing information for full details.

    Drug interactions

    Hepatic enzyme-inducing drugs (including phenytoin, barbiturates, primidone, carbamazepine, and rifampicin), griseofulvin, oxcarbazepine, rifabutin. Oral antidiabetics, insulin, St. John’s wort (hypericum perforatum).
    See prescribing information for full details.

    Bayer Pharma AG
    Licence holder